Drug utilization according to reason for prescribing: A pharmacoepidemiologic method based on an indication hierarchy

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 10, 2012, Pages 1027-1035

  Wallach Kildemoes, Helle ^a,b   Hendriksen, Carsten ^b   Andersen, Morten ^b,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Drug utilization; Indication hierarchy; Pharmacoepidemiologic method; Prescribing indication; Statins

Indexed keywords

ANTIDIABETIC AGENT; CARDIOVASCULAR AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DIABETES MELLITUS; DRUG USE; DRUG UTILIZATION; FEMALE; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SURGERY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DENMARK; DRUG UTILIZATION; FEMALE; HISTORY, 21ST CENTURY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERIPHERAL ARTERIAL DISEASE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION DRUGS; REGISTRIES; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; STROKE;

EID: 84866430011     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2195     Document Type: Article

References (38)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383-1389.
2. Ong HT. The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. QJM 2005; 98(8): 599-614.
3. Shepherd J. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Am J Cardiol 1995; 76(9): 113C-117C.
4. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335(14): 1001-1009.
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339(19): 1349-1357.
6. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 7-22.
7. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149-1158.
8. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): 685-696.
9. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279(20): 1615-1622.
10. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360(9346): 1623-1630.
11. Raymond CB, Morgan SG, Katz A, et al. A population-based analysis of statin utilization in British Columbia. Clin Ther 2007; 29(9): 2107-2119.
12. Teeling M, Bennett K, Feely J. The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002. Br J Clin Pharmacol 2005; 59(2): 227-232.
13. Savoie I, Kazanjian A. Utilization of lipid-lowering drugs in men and women. a reflection of the research evidence? J Clin Epidemiol 2002; 55(1): 95-101.
14. Ruokoniemi P, Helin-Salmivaara A, Klaukka T, et al. Shift of statin use towards the elderly in 1995-2005: a nation-wide register study in Finland. Br J Clin Pharmacol 2008; 66(3): 405-410.
15. DeWilde S, Carey IM, Bremner SA, et al. Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart 2003; 89(4): 417-421.
16. Abookire SA, Karson AS, Fiskio J, et al. Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Arch Intern Med 2001; 161(1): 53-58.
17. Selmer R, Sakshaug S, Skurtveit S, et al. Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. Br J Clin Pharmacol 2009; 67(3): 355-362.
18. Thygesen LC, Daasnes C, Thaulow I, et al. Introduction to Danish nation-wide registers on health and social issues - structure, access, legislation and archiving. Scand J Public Health 2011; 39(Supple 7): 12-16.
19. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011; 39(Supple 7): 38-41.
20. Kildemoes HW, Stovring H, Andersen M. Driving forces behind increasing cardiovascular drug utilization: a dynamic pharmacoepidemiological model. Br J Clin Pharmacol 2008; 66(6): 885-895.
21. Pyorala K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15(10): 1300-1331.
22. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24(17): 1601-1610.
23. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28(19): 2375-2414.
24. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140(2): 199-270.
25. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic). J Vasc Interv Radiol 2006; 17(9): 1383-1397.
26. Christensen B, Heebøll-Nielsen N, Madsen L, et al. Forebyggelse af iskæmisk hjertesygdom i almen praksis - med særligt henblik på dyslipidæmi: En klinisk vejledning [Prevention of ishaemic heart disease in general practice - with special reference to dyslipidemia: A clinical guidance]. Danish Medical Association (DSAM): Aalborg, 1998.
27. Christensen B, Færgemann O, Heebøll-Nielsen N, et al. Forebyggelse af iskæmisk hjerte-kar-sygdom i almen praksis. En klinisk vejledning [Prevention of ischemic cardiovascular disease in almen practice. A clinical guidance.]. Danish Medical Association (DSAM): Denmark, 2007.
28. Thomsen T, Christensen B, Hildebrant P, et al. Kliniske retningslinier for forebyggelse af kardiovaskulær sygdom i Danmark [Clinical guidance for prevention of cardiovasular disease in Denmark]. The European Society of Cardiology: Denmark, 2004.
29. Færgemann O, Christensen B, Hansen HS, et al. Sekundær og primær forebyggelse af koronar hjertesygdom med særligt henblik på dyslipidæmi [Secondary and primary prevention of coronar heart disease ved speciel reference to dydlipedemia]. Danish Society of Cardiology: Denmark, 2000.
30. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24(11): 987-1003.
31. Petersen CB. The Danish Civil Registration System. Scand J Public Health 2011; Suppl (in press).
32. Hallas J, Stovring H. Templates for analysis of individual-level prescription data. Basic Clin Pharmacol Toxicol 2006; 98(3): 260-265.
33. WHO Collaborating centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment, 2010. Norwegian Institute of Public Health: Oslo, 2009.
34. Andersen TF, Madsen M, Jorgensen J, et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46(3): 263-268.
35. Cannon PJ, Connell PA, Stockley IH, et al. Prevalence of angina as assessed by a survey of prescriptions for nitrates. Lancet 1988; 1(8592): 979-981.
36. Gray J, Majeed A, Kerry S, et al. Identifying patients with ischaemic heart disease in general practice: cross sectional study of paper and computerised medical records. BMJ 2000; 321(7260): 548-550.
37. Jensen HK. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark. Dan Med Bull 2002; 49(4): 318-345.
38. Larsen J, Vaccheri A, Andersen M, et al. Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. Br J Clin Pharmacol 2000; 49(5): 463-471.